Zheng Quan Ri Bao Zhi Sheng·2026-01-06 13:09Core Viewpoint - The company has a diverse and competitive vaccine product portfolio with significant market potential both domestically and internationally [1] Group 1: Domestic and International Market Strategy - The company has strategically selected target countries and regions for expansion, including Southeast Asia, the Middle East, South America, and North Africa [1] - The company has identified unmet clinical needs in the vaccine sector, which will be a focus for future international expansion [1] Group 2: Product Development and Commercialization - The company is currently working on the commercialization of candidate products such as the 13-valent pneumococcal conjugate vaccine and the DTP vaccine for international markets [1] - The company plans to leverage product characteristics and combinations to further expand its overseas commercialization efforts [1] Group 3: Collaboration and Local Production - The company aims to promote the internationalization of its key products through diverse collaboration models, including joint research and the establishment of localized production systems [1] - Future strategies will involve adapting to local market needs through various cooperative models to explore broader international markets [1]